84 phenotypes from 7 alleles in 14 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Ifngr1em1(IMPC)Mbp/Ifngr1em1(IMPC)Mbp C57BL/6N-Ifngr1em1(IMPC)Mbp/MbpMmucd	abnormal eye morphology	J:211773
	abnormal skin morphology	J:211773
	abnormal vitreous body morphology	J:211773
	cataract	J:211773
	preweaning lethality, incomplete penetrance	J:211773
Ifngr1m1Btlr/Ifngr1m1Btlr C57BL/6J-Ifngr1m1Btlr	decreased macrophage cell number	J:236694
	decreased tumor necrosis factor secretion	J:236694
	impaired hematopoiesis	J:236694
	increased B cell number	J:236694
Ifngr1tm1.1Rds/Ifngr1tm1.1Rds Commd10Tg(Vav1-icre)A2Kio/Commd10+ B6NTac.Cg-Ifngr1tm1.1Rds Commd10Tg(Vav1-icre)A2Kio	increased susceptibility to bacterial infection	J:206257
	increased susceptibility to bacterial infection induced morbidity/mortality	J:206257
Ifngr1tm1.1Rds/Ifngr1tm1.1Rds Tg(Itgax-cre,-EGFP)4097Ach/0 B6NTac.Cg-Ifngr1tm1.1Rds Tg(Itgax-cre,-EGFP)4097Ach	decreased interferon-gamma secretion	J:206257
	decreased interleukin-12b secretion	J:206257
	increased susceptibility to bacterial infection	J:206257
	increased susceptibility to bacterial infection induced morbidity/mortality	J:206257
Ifngr1tm1.1Rost/Ifngr1tm1.1Rost involves: BALB/cJ * C57BL/6	abnormal chemokine level	J:152785
	decreased circulating interferon-gamma level	J:152785
	decreased circulating interleukin-12 level	J:152785
	decreased metastatic potential	J:152785
	normal immune system phenotype	J:152785
Ifngr1tm1.2Rds/Ifngr1tm1.2Rds C57BL/6NTac-Ifngr1tm1.2Rds	decreased interleukin-12b secretion	J:206257
	increased susceptibility to bacterial infection	J:206257
	increased susceptibility to bacterial infection induced morbidity/mortality	J:206257
Ifngr1tm1Agt/Ifngr1tm1Agt 129-Ifngr1tm1Agt/J	normal immune system phenotype	J:286237
Ifngr1tm1Agt/Ifngr1tm1Agt B6.129S7-Ifngr1tm1Agt	abnormal myelination	J:108669
	abnormal pain threshold	J:158280
	decreased physiological sensitivity to xenobiotic	J:108669
Ifngr1tm1Agt/Ifngr1tm1Agt B6.129S7-Ifngr1tm1Agt/J	abnormal circulating chemokine level	J:152785
	abnormal depression-related behavior	J:147443
	abnormal hematopoietic system physiology	J:138728
	abnormal lymphopoiesis	J:138728
	abnormal osteoclast differentiation	J:233116
	decreased bone marrow cell number	J:138728
	decreased bone mineralization	J:233116
	decreased bone ossification	J:233116
	decreased bone resorption	J:233116
	decreased bone trabecula number	J:233116
	decreased bone volume	J:233116
	decreased CD4-positive, alpha-beta T cell number	J:138728
	decreased CD8-positive, alpha-beta T cell number	J:138728
	decreased circulating interleukin-12 level	J:152785
	decreased circulating osteocalcin level	J:233116
	decreased compact bone thickness	J:233116
	decreased lymphocyte cell number	J:138728
	decreased osteoblast cell number	J:233116
	decreased osteocyte number	J:233116
	decreased susceptibility to bacterial infection	J:147443
	decreased trabecular bone thickness	J:233116
	impaired osteoblast differentiation	J:233116
	increased interferon-gamma secretion	J:138728
	increased metastatic potential	J:152785
	increased susceptibility to graft versus host disease	J:138728
	increased susceptibility to induced morbidity/mortality	J:138728
	osteoporosis	J:233116
	spleen hypoplasia	J:138728
Ifngr1tm1Agt/Ifngr1tm1Agt involves: 129S7/SvEvBrd	abnormal immunoglobulin level	J:38363, J:101427
	abnormal maternal decidual layer morphology	J:56503
	abnormal response to infection	J:115139
	abnormal tumor susceptibility	J:63089
	abnormal tumor vascularization	J:63089
	abnormal uterine NK cell morphology	J:56503
	abnormal uterine NK cell physiology	J:56503
	abnormal uterus morphology	J:56503
	abnormal vascular endothelial cell physiology	J:114203
	aortitis	J:115139
	arteritis	J:115139
	decreased circulating tumor necrosis factor level	J:17878
	decreased IgG2a level	J:38363
	decreased susceptibility to endotoxin shock	J:17878
	increased circulating interferon-gamma level	J:314959
	increased circulating interleukin-1 beta level	J:314959
	increased circulating interleukin-6 level	J:174397
	increased hepatocyte proliferation	J:38363
	increased interferon-gamma secretion	J:38363
	increased susceptibility to bacterial infection	J:174397, J:314959
	increased susceptibility to bacterial infection induced morbidity/mortality	J:174397, J:314959
	increased susceptibility to experimental autoimmune encephalomyelitis	J:38363
	increased susceptibility to Herpesvirales infection	J:81243
	increased susceptibility to Herpesvirales infection induced morbidity/mortality	J:115139
	increased susceptibility to induced morbidity/mortality	J:38363
	increased susceptibility to parasitic infection	J:114203
	increased susceptibility to Poxviridae infection	J:101427
	increased tumor necrosis factor secretion	J:38363
	increased uterine NK cell number	J:56503
	liver abscess	J:174397
Ifngr1tm1Agt/Ifngr1tm1Agt involves: 129S7/SvEvBrd * C57BL/6	abnormal cytotoxic T cell physiology	J:63815
	abnormal tumor susceptibility	J:138466
	decreased IgG2a level	J:63815
	decreased IgG3 level	J:63815
	decreased susceptibility to experimental autoimmune myasthenia gravis	J:53577
	increased interferon-gamma secretion	J:99347
	increased interleukin-6 secretion	J:99347
	increased splenocyte proliferation	J:99347
	increased susceptibility to bacterial infection	J:63815
	increased susceptibility to experimental autoimmune uveoretinitis	J:99347
	increased susceptibility to Riboviria infection	J:63815
	increased susceptibility to Riboviria infection induced morbidity/mortality	J:63815
	normal liver/biliary system phenotype	J:120559
Ifngr1tm1Agt/Ifngr1tm1Agt involves: 129S7/SvEvBrd * DBA/1OlaHsd	decreased IgG2a level	J:40634
	increased susceptibility to induced arthritis	J:40634
Ifngr1tm1Dmer/Ifngr1tm1Dmer B6.Cg-Ifngr1tm1Dmer	abnormal response to infection	J:202844
Ifngr1tm1Dmer/Ifngr1tm1Dmer Tg(Thy1-cre)1Vln/0 B6.Cg-Ifngr1tm1Dmer Tg(Thy1-cre)1Vln	abnormal response to infection	J:202844